US-12622855-B1 - Hyperpigmentation treatment cream and serum

Abstract

Compositions for skin creams and serums are provided for treating skin hyperpigmentation, the compositions including cysteamine, tranexamic acid, niacinamide, tetrapeptide 30, DNA repair enzymes, and human growth factors. A formulation for the skin cream or serum includes 5% cysteamine by weight, 5% tranexamic acid by weight, 4% niacinamide by weight, 1% tetrapeptide 30 by weight, in which the tetrapeptide 30 includes the following four amino acids linked together: L-prolyl-L-lysyl-L-alpha-glutamyl-L-lysine. In addition, the cream or serum includes DNA repair enzymes, including 1% phytosomes, 0.3 to 1% roxisomes, and 1% ultrasomes. Further, the composition may include recombinant human growth factors.

Inventors

• Mitchell Schwartz

Assignees

• ProCell Therapies, LLC

Dates

Publication Date

20260512

Application Date

20241227

Claims (2)

1. 1 . A composition for treating skin hyperpigmentation consisting of: about 5 wt % tranexamic acid; about 4 wt % niacinamide; about 0.20 wt % phytic acid; about 5 wt % cysteamine hydrochloride; about 1 wt % plankton extract; about 1 wt % lecithin; about 1 wt % Arabidopsis thaliana extract; about 1 wt % micrococcus lysate; about 0.01 wt % of one or more recombinant human growth factors selected from the group consisting of sh-polypeptide-62, sh-polypeptide-1, sh-polypeptide-11, sh-polypeptide-31, acetyl octapeptide-17 amide, sh-oligopeptide-2, sh-polypeptide-10, and acetyl sh-oligopeptide-77; about 1 wt % tetrapeptide-30; about 60 wt % base solvent; about 7 wt % emulsifiers; about 2 wt % emollients; about 6.2 wt % skin moisturizing compounds; about 5 wt % emulsion thickeners; about 2 wt % odor masking agents; about 0.1 wt % chelating agents; and about 1 wt % preservatives.
2. 2 . The composition of claim 1 , wherein the base solvent is water.

Description

RELATED APPLICATION DATA This application claims the benefit of priority of U.S. Provisional Patent Application Ser. No. 63/615,034, filed Dec. 27, 2023, and titled “Hyperpigmentation Cream and Serum,” which is incorporated by reference herein in its entirety. FIELD The present disclosure relates to the field of skin care compositions, and more specifically to creams or serums for treating hyperpigmentation. BACKGROUND While the use of growth factors and other chemicals to treat aging skin are known, there remains a need for more effective topical and microchanneling treatment formulations for the prevention and treatment of many skin conditions, and in particular the prevention and treatment of hyperpigmentation. SUMMARY OF THE DISCLOSURE A composition for treating skin hyperpigmentation is disclosed that includes 2 wt %-8 wt % cysteamine, 2 wt %-8 wt % tranexamic acid, 1 wt %-7 wt % niacinamide, 0.1 wt %-2 wt % tetrapeptide 30, 0.1 wt %-2 wt % phytosomes, 0.3 wt % to 1 wt % roxisomes, 0.1 wt %-2 wt % ultrasomes, and a plurality of recombinant human growth factors selected from the group of sh-polypeptide-1, sh-polypeptide-11, sh-polypeptide-31, sh-oligopeptide-2, sh-polypeptide-10, sh-polypeptide-5, sh-polypeptide-8, sh-polypeptide-3, sh-polypeptide-62, acetyl octapeptide-17 amide, sh-oligopeptide-1, sh-polypeptide-4, and acetyl sh-oligopeptide77 amide, wherein the plurality of recombinant human growth factors have in combination a concentration ranging from 0.001 wt % to 1 wt %. The tetrapeptide 30 may include L-prolyl amino acid, L-lysyl amino acid, L-alpha-glutamyl amino acid, and L-lysine amid acid linked together. The composition may also include water, glyceryl stearate citrate, tocopherol, and trisodium dicarboxymethyl alaninateone. In another aspect, a composition for treating skin hyperpigmentation includes about 5 wt % tranexamic acid, about 4 wt % niacinamide, about 0.20 wt % phytic acid, about 2.5 wt % cysteamine hydrochloride, about 1 wt % plankton extract, about 1 wt % lecithin, about 1 wt % Arabidopsis thaliana extract, about 1 wt % micrococcus lysate, about 0.01 wt % of recombinant human growth factors one or more from the group consisting of sh-polypeptide-62, sh-polypeptide-1, sh-polypeptide-11, sh-polypeptide-31, acetyl octapeptide-17 amide, sh-oligopeptide-2, sh-polypeptide-10, and acetyl sh-oligopeptide-77, and about 1 wt % tetrapeptide-30. Additionally, a composition for treating skin hyperpigmentation includes about 5 wt % tranexamic acid, about 4 wt % niacinamide, about 0.20 wt % phytic acid, about 5 wt % cysteamine hydrochloride, about 1 wt % plankton extract, about 1 wt % lecithin, about 1 wt % Arabidopsis thaliana extract, about 1 wt % micrococcus lysate, about 0.01 wt % of recombinant human growth factors one or more from the group consisting of sh-polypeptide-62, sh-polypeptide-1, sh-polypeptide-11, sh-polypeptide-31, acetyl octapeptide-17 amide, sh-oligopeptide-2, sh-polypeptide-10, and acetyl sh-oligopeptide-77, and about 1 wt % tetrapeptide-30. A method of reducing the appearance of hyperpigmentation is disclosed that includes identifying a target portion of skin exhibiting hyperpigmentation and applying an effective amount of a skin care composition to the target portion of skin over a course of a treatment period. The skin care composition comprises about 5 wt % tranexamic acid, about 4 wt % niacinamide, about 0.20 wt % phytic acid, about 5 wt % cysteamine hydrochloride, about 1 wt % plankton extract, about 1 wt % lecithin, about 1 wt % Arabidopsis thaliana extract, about 1 wt % micrococcus lysate, about 0.01 wt % of recombinant human growth factors one or more from the group consisting of sh-polypeptide-62, sh-polypeptide-1, sh-polypeptide-11, sh-polypeptide-31, acetyl octapeptide-17 amide, sh-oligopeptide-2, sh-polypeptide-10, and acetyl sh-oligopeptide-77, and about 1 wt % tetrapeptide-30. DETAILED DESCRIPTION Compositions for skin creams and serums are provided for treating skin hyperpigmentation, the compositions including cysteamine, tranexamic acid, niacinamide, tetrapeptide 30, DNA repair enzymes, and human growth factors. In an embodiment, a formulation for a skin cream or serum includes 5% cysteamine by weight, 5% tranexamic acid by weight, 4% niacinamide by weight, 1% tetrapeptide 30 by weight, in which the tetrapeptide 30 includes the following four amino acids linked together: L-prolyl-L-lysyl-L-alpha-glutamyl-L-lysine. In addition, the cream or serum includes DNA repair enzymes, including 1% phytosomes, 0.3 to 1% roxisomes, and 1% ultrasomes. Further, the composition may include recombinant human growth factors, including a plurality of recombinant human growth factors selected from sh-polypeptide-1, sh-polypeptide-11, sh-polypeptide-31, sh-oligopeptide-2, sh-polypeptide-10, sh-polypeptide-5, sh-polypeptide-8, sh-polypeptide-3, sh-polypeptide-62, acetyl octapeptide-17 amide, sh-oligopeptide-1, sh-polypeptide-4, and acetyl sh-oligopeptide77 amide, in which th